For instance, Pamrevlumab (FG-3019) is a connective tissue growth factor (CTGF) inhibitor that interferes with cancer-associated fibroblasts (CAF) activity to reduce extracellular matrix remodeling [23]. This evidence concerns the gene CCN2 and cancer.